United Kingdom
The Netherlands, Switzerland, Austria, Italy, Sweden, Denmark, France, Poland
Israel, Greece

Erasmus Medical Centre

Erasmus Universitair Medisch Centrum Rotterdam (EMC)

The Erasmus Medical Centre is one of the largest academic hospitals in Western Europe, employing more than 14,000 people, with researchers being involved in more than 221 EU-financed projects. The department of Medical Microbiology and Infectious Diseases at the Erasmus MC employs approximately 100 people, 35 of which are involved in research. Various departmental research projects are ongoing, with the most extensive research is being performed into the mechanisms of antimicrobial resistance, their detection and characterization (using novel diagnostic technologies). Other major interests and project based research include pk/pd, tuberculosis, staphylococcal, campylobacter and fungal research. The department has many years of experience in animal models of infection, coupled to antimicrobial resistance and drug efficacy studies. The department is currently involved in more than 20 externally funded projects and is currently coordinator of the EU FP7 projects TEMPOtest-QC, NABARSI and Tailored-Treatment.

Main tasks
Erasmus MC is responsible for WP6 (project management): Erasmus MC will support the project coordinator in the operational project management tasks and be responsible for the administrative, financial and legal issues. This partner will also contribute to the dissemination activities in WP5. In addition, Eramus MC is the WP leader of WP4 and will coordinate the pharmacokinetic and pharmacodynamic studies and perform part of the work.

Previous experience
Several animal infection models were developed and are available for PK/PD studies. Recently sensitive qPCR methods have been developed as outcome parameter. There is significant experience in surveillance and epidemiology of resistance as well as rational use of antibiotics. Population pharmaco-kinetic modeling is one of the new key areas of research for all anti-infectives. Therapeutic Drug Monitoring of anti-infectives is performed for both national and international study sites
Eramus MC is involved as partner in many FP6 and FP7 projects and, moreover, has extensive experience in the coordination of FP-Projects. Johan W. Mouton is a partner and WP leader in the FP7 project SATURN and involved in many collaborative projects and research activities.

Key personnel
Johan W Mouton (MD, PhD) was trained as a medical scientist as well as medical Microbiologist. His research focused on two main areas: epidemiology of resistance and antimicrobial pharmacodynamics. He served as the president of the International Society of Antiinfective Pharmacology and is member of the steering committee of EUCAST (European Committee on Antimicrobial Susceptibility Testing), among other offices. He has published >150 papers in peer‐reviewed scientific journals, among which several collaborative papers to standardize approaches in the field.
Dr. W.H.F. Goessens (Group Leader at the Dept. of Medical Microbiology & Infectious Diseases, Erasmus MC) is an expert in the etiology of Extended Spectrum β-Lactamase (ESBL) carrying pathogens. His research revolves around factors involved in the enhancement of mutations leading to ESBL resistance, the prevention of resistance selection in vivo, and studying the relationship of membrane permeability and the level of β-lactam resistance. His lab has extensive expertise in diagnostic screening of microbials. He has published over 70 publications relating to antimicrobial resistance, and is currently leading research into pAmpC resistance funded by a Dutch ZonMW grant. He is also involved as a principle investigator in a European FP7 project entitled: “New AntiBacterials with Inhibitory activity on Aminoacyl-tRNA Synthetases”

Recent publications